Retroviral-mediated modification of immune cells, such as T and NK cells, with chimeric antigen receptors (CAR) has been used to improve treatment options for cancer patients, most prominently those with CD19+ lymphoid malignancies [3,4,5,6,7,8]. This evidence concerns the gene CD19 and cancer.